# Precision treatment of gastrointestinal tumours and liver disease interaction mechanisms based on multi-omics data and microbiome hubs

## TL;DR

This review explores how multi-omics data and gut microbiome interactions can improve the precision treatment of gastrointestinal tumors and liver disease.

## Contribution

The paper highlights novel insights into the gut microbiota's role in tumor development and its connection to liver disease via the gut-liver axis.

## Key findings

- Multi-omics technologies are decoding the genetic architecture of gastrointestinal tumors.
- The gut microbiota influences tumorigenesis through immune and metabolic mechanisms.
- The gut-liver axis mediates a cycle linking liver disease and tumors.

## Abstract

The global prevalence of gastrointestinal tumours and the bottlenecks in their diagnosis and treatment are being systematically overcome by the multi-omics revolution: high-throughput technologies are driving the multidimensional integration of genomics-transcriptomics-proteomics-metabolomics to comprehensively decode the genetic architecture of tumours. Meanwhile, the gut microbiota, acting as a core regulatory hub, drives carcinogenesis through immune microenvironment remodelling and metabolic pathway hijacking, further facilitating proteome-metabolome multidimensional integration, comprehensively decoding tumour genetic architecture. The gut microbiota, acting as a core regulatory hub, drives carcinogenesis through immune microenvironment remodelling and metabolic pathway hijacking, while mediating a vicious cycle network linking liver disease and tumours via the gut-liver axis. This review examines the application of multi-omics technologies in gastrointestinal tumour research, summarises the role of gut microbiota in tumourigenesis and its interaction with liver disease, and envisions future interventions targeting the gut microbiome for early disease diagnosis and precision treatment.